BioSpace News Archive

Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with non-valvular atrial fibrillation (NVAF).

M6P Therapeutics Announces Presentation at the Upcoming 16 th International Symposium of MPS and Related Diseases - Oral Presentation on Friday, July 23, 2021 @ 11:25 a.m. ET / 17:25 p.m. CEST -

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, for the treatment of ‘Prolonged COVID-19 Symptoms’ (“Long Haulers”).

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announces that the innovative AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged 6 years and older.

IM Therapeutics today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D).

Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, August 17.

Peter K Honig, MD, MPH and Michael A.S. Jewett, MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021

Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

The Fact.MR market analysis on the medical foam market highlights increasing application in medical packaging, braces, and hydrophilic dressings among others as primary growth enabler.

BioArctic AB’s partner Eisai will hold several presentations at the Alzheimer’s Association International Conference to be held in Denver, Colorado and virtually from July 26 to 30, 2021.